Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Aug 1, 2024
Date Accepted: Oct 15, 2024

The final, peer-reviewed published version of this preprint can be found here:

The Prevalence of Sickle Cell Disease in Colorado and Methodologies of the Colorado Sickle Cell Data Collection Program: Public Health Surveillance Study

Miller JI, Hassell KL, Kellar-Guenther Y, Quesada S, West R, Sontag M

The Prevalence of Sickle Cell Disease in Colorado and Methodologies of the Colorado Sickle Cell Data Collection Program: Public Health Surveillance Study

JMIR Public Health Surveill 2024;10:e64995

DOI: 10.2196/64995

PMID: 39652892

PMCID: 11649251

The Prevalence of Sickle Cell Disease in Colorado and Methodologies of the Colorado Sickle Cell Data Collection Program: Public Health Surveillance

  • Joshua I Miller; 
  • Kathryn L Hassell; 
  • Yvonne Kellar-Guenther; 
  • Stacey Quesada; 
  • Rhonda West; 
  • Marci Sontag

ABSTRACT

Background:

Sickle cell disease (SCD) is a hereditary blood disorder causing significant health complications. While advancements in care have improved survival rates, accurate prevalence data in Colorado has been limited, hampering effective public health interventions.

Objective:

The objectives of this study were to establish and describe the Colorado Sickle Cell Data Collection (CO-SCDC) program, update the prevalence and birth prevalence of sickle cell disease (SCD) in Colorado, and improve surveillance methodologies to inform public health interventions, education initiatives, and policy development.

Methods:

The CO-SCDC program collected and linked data from multiple sources including the Colorado Department of Health and Environment and electronic health records from University of Colorado Health and Children’s Hospital Colorado. Data from 2012 to 2020 were analyzed using national case definitions to classify SCD cases. Case validation was performed via clinical review by two hematologists. Prevalence and birth prevalence of SCD in Colorado were calculated as were demographics of the Colorado SCD population.

Results:

In 2019, 435 individuals were identified as living with SCD in Colorado, an increase of 16-40% over previous estimates. The prevalence of SCD was highest in urban counties, with concentrations in Arapahoe, Denver, and El Paso counties. Birth prevalence of SCD increased from 11.9 per 100,000 live births between 2010-2014 to 20.1 per 100,000 live births between 2015-2019. The study highlighted a 67% increase in SCD births over the decade, correlating with the growth of the Black or African American population in the state.

Conclusions:

The CO-SCDC program successfully established a capacity to perform SCD surveillance and a baseline of prevalence estimates for SCD in Colorado. The findings underscore the importance of surveillance for informed public health strategies and policy development to improve outcomes for individuals with SCD.


 Citation

Please cite as:

Miller JI, Hassell KL, Kellar-Guenther Y, Quesada S, West R, Sontag M

The Prevalence of Sickle Cell Disease in Colorado and Methodologies of the Colorado Sickle Cell Data Collection Program: Public Health Surveillance Study

JMIR Public Health Surveill 2024;10:e64995

DOI: 10.2196/64995

PMID: 39652892

PMCID: 11649251

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.